Byooviz (ranibizumab-nuna) NDC 64406-019 · J-Code J2778

NDC codes

FDA NDC Directory

Product NDC (as listed)64406-019Labeler and product segments. Claims need a package NDC.

Product NDC at billing width64406-0019Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
64406-019-01	64406001901	1 VIAL, SINGLE-DOSE in 1 CARTON (64406-019-01) / .05 mL in 1 VIAL, SINGLE-DOSE (64406-019-07)Marketed from Jun 1, 2022
64406-019-08	64406001908	1 VIAL, SINGLE-DOSE in 1 CARTON (64406-019-08) / .05 mL in 1 VIAL, SINGLE-DOSE (64406-019-09)Marketed from Oct 3, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Byooviz
Generic name (nonproprietary): ranibizumab-nuna
Active ingredients: Ranibizumab — 10 mg/mL
Dosage form: Injection, Solution
Route: Intravitreal
Labeler: BIOGEN INC.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761202
Marketing start: Jun 1, 2022
Marketing end: Jul 19, 2028
Other FDA classes: Vascular Endothelial Growth Factor Inhibitors (Mechanism)
Identifiers: Product ID 64406-019_44ead429-973b-60cb-e063-6394a90a9a75SPL ID 44ead429-973b-60cb-e063-6394a90a9a75SPL set ID e46db299-edd1-4457-89b2-c1e2e505f1b0RxCUI 2602353, 2602359UNII ZL1R02VT79
Pharmacologic class: Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J2778 — Injection, ranibizumab, 0.1 mg

Billing unit: 0.1 mg. Units on the claim = dose given ÷ 0.1 mg.

Ranibizumab biosimilars and the ranibizumab implant have their own HCPCS codes.

Administration

Intravitreal injection procedure (CPT 67028)

The intravitreal injection is reported as a separate procedure from the drug supplied.

How CPT relates to drug billing

NDC on a medical claim

N464406001901 followed by a unit qualifier and the quantity

Package 64406-0019-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 1, 2025.

Indications (excerpt from the label)

BYOOVIZ is indicated for the treatment of patients with: BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Myopic Choroidal Neovascularization (mCNV) ( 1.3 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Myopic Choroidal Neovascularization (mCNV)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761202

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761202
Product	Strength	Form · route	Labeler	Product NDC
Byoovizranibizumab-nuna	Ranibizumab 10 mg/mL	Injection, SolutionIntravitreal	Harrow Eye, LLC	82667-018